MCID: VSC004
MIFTS: 28

Vasculogenic Impotence

Categories: Cardiovascular diseases, Mental diseases

Aliases & Classifications for Vasculogenic Impotence

MalaCards integrated aliases for Vasculogenic Impotence:

Name: Vasculogenic Impotence 12 15 17
Impotence, Vasculogenic 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4762
MeSH 43 D018783
UMLS 71 C0243000

Summaries for Vasculogenic Impotence

MalaCards based summary : Vasculogenic Impotence, also known as impotence, vasculogenic, is related to impotence and vascular disease. An important gene associated with Vasculogenic Impotence is PDE5A (Phosphodiesterase 5A), and among its related pathways/superpathways is Renin secretion. The drugs Everolimus and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include testes, smooth muscle and skin, and related phenotype is cardiovascular system.

Related Diseases for Vasculogenic Impotence

Diseases related to Vasculogenic Impotence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 impotence 31.0 PDE5A PDE4A ACE
2 vascular disease 10.3
3 priapism 10.3
4 peyronie's disease 10.2
5 venous insufficiency 10.2
6 raynaud disease 10.1 PDE5A ACE
7 chronic pulmonary heart disease 10.1 PDE5A ACE
8 tricuspid valve insufficiency 10.1 PDE5A ACE
9 tricuspid valve disease 10.1 PDE5A ACE
10 buerger disease 10.1
11 arteriosclerosis 10.1
12 intermittent claudication 10.1
13 nonarteritic anterior ischemic optic neuropathy 10.1 PDE5A ACE
14 limited scleroderma 10.0 PDE5A ACE
15 hypoaldosteronism 10.0 NPPA ACE
16 anterolateral myocardial infarction 10.0 NPPA ACE
17 hypertension, diastolic 10.0 NPPA ACE
18 idiopathic edema 10.0 NPPA ACE
19 renal artery disease 10.0 NPPA ACE
20 central sleep apnea 10.0 NPPA ACE
21 mitral valve stenosis 10.0 NPPA ACE
22 acute kidney tubular necrosis 10.0 NPPA ACE
23 hepatorenal syndrome 10.0 NPPA ACE
24 mitral valve insufficiency 9.9 NPPA ACE
25 malignant hypertension 9.9 NPPA ACE
26 renovascular hypertension 9.9 NPPA ACE
27 pericardial effusion 9.9 NPPA ACE
28 hypertensive heart disease 9.9 NPPA ACE
29 systolic heart failure 9.9 NPPA ACE
30 mitral valve disease 9.9 NPPA ACE
31 collagen disease 9.9 NPPA ACE
32 heart valve disease 9.9 NPPA ACE
33 nasopharyngitis 9.9 PDE5A PDE4A
34 pulmonary edema 9.9 NPPA ACE
35 intrinsic cardiomyopathy 9.8 NPPA ACE
36 optic nerve disease 9.8 PDE5A ACE
37 atrial standstill 1 9.8 NPPA ACE
38 aortic valve disease 2 9.8 NPPA ACE
39 restrictive cardiomyopathy 9.8 SYNE2 ACE
40 atrial heart septal defect 9.8 NPPA ACE
41 trypanosomiasis 9.8 NPPA ACE
42 pure autonomic failure 9.7 PDE5A NPPA ACE
43 diastolic heart failure 9.7 PDE5A NPPA ACE
44 pulmonary embolism 9.7 PDE5A NPPA ACE
45 congestive heart failure 9.7 PDE5A NPPA ACE
46 cardiovascular system disease 9.6 PDE5A NPPA ACE
47 lipid metabolism disorder 9.6 PDE5A ACE
48 myocarditis 9.6 NPPA ACE
49 pre-eclampsia 9.6 PDE5A NPPA ACE
50 sexual disorder 9.5 PDE5A PDE4A ACE

Graphical network of the top 20 diseases related to Vasculogenic Impotence:



Diseases related to Vasculogenic Impotence

Symptoms & Phenotypes for Vasculogenic Impotence

MGI Mouse Phenotypes related to Vasculogenic Impotence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.02 ACE NPPA PDE4A PTS SYNE2

Drugs & Therapeutics for Vasculogenic Impotence

Drugs for Vasculogenic Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
2
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
3
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
4 Anti-Infective Agents Phase 2, Phase 3
5 Immunologic Factors Phase 2, Phase 3
6 Antibiotics, Antitubercular Phase 2, Phase 3
7 Antifungal Agents Phase 2, Phase 3
8 Anti-Bacterial Agents Phase 2, Phase 3
9 Immunosuppressive Agents Phase 2, Phase 3
10
Coal tar Approved Phase 1, Phase 2 8007-45-2
11 Anesthetics Phase 1, Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients With Internal Pudendal Artery-Related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB) Unknown status NCT02492386 Phase 2, Phase 3
2 Effectiveness and Safety of Intracavernosal Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction Completed NCT02472431 Phase 1, Phase 2

Search NIH Clinical Center for Vasculogenic Impotence

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprostadil
Pentoxifylline
sildenafil
Sildenafil citrate

Cochrane evidence based reviews: impotence, vasculogenic

Genetic Tests for Vasculogenic Impotence

Anatomical Context for Vasculogenic Impotence

MalaCards organs/tissues related to Vasculogenic Impotence:

40
Testes, Smooth Muscle, Skin, Prostate, Endothelial

Publications for Vasculogenic Impotence

Articles related to Vasculogenic Impotence:

(show top 50) (show all 223)
# Title Authors PMID Year
1
Hybrid Endovascular Aortic Aneurysm Repair: Preservation of Pelvic Perfusion with External to Internal Iliac Artery Bypass. 61
28286187 2017
2
[Aorto-femoral reconstructions in patients with vasculogenic impotence and quality of life]. 61
29898292 2017
3
Endovascular treatment of vasculogenic erectile dysfunction. 61
25532580 2015
4
Sympathetic skin response in patients with vascular erectile dysfunction. 61
24872950 2014
5
Nocturnal penile erections: the role of RigiScan in the diagnosis of vascular erectile dysfunction. 61
23206346 2012
6
The role of Doppler ultrasound in the diagnosis of vasculogenic impotence. 61
21341552 2010
7
Office management of peripheral arterial disease. 61
20800143 2010
8
Predictive value of cavernosal peak systolic velocity in the flaccid penis. 61
19808161 2009
9
Feasibility of dynamic 3-D color Doppler ultrasound for imaging penile vascular change in renal transplant patients with erectile dysfunction responding to sildenafil. 61
18295391 2008
10
Purification of a dimethyladenosine compound from silkworm pupae as a vasorelaxation substance. 61
18337035 2008
11
Vasculogenic impotence as a symptom in late-onset Buerger's disease. 61
17486572 2007
12
Penile oxygen saturation in the flaccid and erect penis in men with and without erectile dysfunction. 61
17021333 2007
13
Peripheral arterial disease in the elderly. 61
18225466 2007
14
Management of peripheral arterial disease of the lower extremities. 61
18025617 2007
15
Corpus cavernosum from men with vasculogenic impotence is partially resistant to adenosine relaxation due to endothelial A(2B) receptor dysfunction. 61
16837560 2006
16
The penile vasculature in systemic sclerosis: A duplex ultrasound study. 61
16681482 2006
17
Automated bedside measurement of penile blood flow using pulse-volume plethysmography. 61
16493536 2006
18
Management of peripheral arterial disease. 61
15705252 2005
19
Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy. 61
15764414 2005
20
Management of peripheral arterial disease of the lower extremities in elderly patients. 61
14999033 2004
21
Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. 61
14713808 2004
22
Autonomic nerve preserving total mesorectal excision. 61
12507206 2002
23
Penile colour duplex ultrasonography as a screening tool for venogenic erectile dysfunction. 61
11957552 2002
24
Decreased trabecular smooth muscle and caveolin-1 expression in the penile tissue of aged rats. 61
11458126 2001
25
Therapeutic effects of high-dose isoxsuprine in the management of mixed-type impotence. 61
11445487 2001
26
Vasculogenic impotence. Arterial and venous surgery. 61
11402583 2001
27
Hemodynamic insult by vascular risk factors and pharmacologic erection in men with erectile dysfunction: Doppler sonography study. 61
11204263 2000
28
[Doppler color ultrasonography in patients with erectile dysfunction]. 61
11221074 2000
29
Vasculogenic impotence and cavernosal oxygen tension. 61
11052643 2000
30
Vasculogenic impotence and cavernosal oxygen tension. 61
10982308 2000
31
Retrospective review of flow patterns following retropubic prostatectomy. 61
10637457 1999
32
Assessment of the functional role of accessory pudendal arteries in erection by transrectal color Doppler ultrasound. 61
10569553 1999
33
Evaluation and therapeutic approaches of voiding and erectile dysfunction in neurological Behçet's syndrome. 61
10379759 1999
34
Recent advancement in diagnosis of vasculogenic impotence. 61
11225903 1999
35
[Revascularization of the corpora cavernosa in vasculogenic impotence]. 61
10429426 1999
36
Penile arteriography. 61
10458660 1999
37
Predictive value of patient history and correlation of nocturnal penile tumescence, colour duplex Doppler ultrasonography and dynamic cavernosometry and cavernosography in the evaluation of erectile dysfunction. 61
10098954 1999
38
Is obesity an underlying factor in erectile dysfunction? 61
10364658 1999
39
Venous incompetence in erectile dysfunction: evaluation with color-coded duplex sonography and cavernosometry/-graphy. 61
9933376 1999
40
Corporeal veno-occlusive dysfunction: a distal arterial pathology? 61
9817322 1998
41
Technetium-99m-labelled RBC erection penogram to differentiate psychogenic from vasculogenic impotence. 61
9792979 1998
42
[Methodology of penile isotope imaging. Evaluation]. 61
9611353 1998
43
Cavernous arterial and arteriolar circulation in patients with erectile dysfunction: a power Doppler study. 61
9649256 1998
44
Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. 61
9334594 1997
45
Laparoscopically assisted penile revascularization for vasculogenic impotence: 2 additional cases. 61
9334601 1997
46
Microrevascularisation of the penis in vascular impotence. 61
9315489 1997
47
Penile revascularisation for vascular impotence. 61
9339093 1997
48
Laparoscopic mobilization of the inferior epigastric artery for penile revascularization in vasculogenic impotence. 61
9250921 1997
49
Relationship between cavernosal ischemia and corporal veno-occlusive dysfunction in an animal model. 61
9072535 1997
50
[Diagnostic methods and therapeutic options in vasculogenic impotence]. 61
9102618 1997

Variations for Vasculogenic Impotence

Expression for Vasculogenic Impotence

Search GEO for disease gene expression data for Vasculogenic Impotence.

Pathways for Vasculogenic Impotence

Pathways related to Vasculogenic Impotence according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.46 NPPA ACE

GO Terms for Vasculogenic Impotence

Biological processes related to Vasculogenic Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of blood pressure GO:0008217 8.62 NPPA ACE

Molecular functions related to Vasculogenic Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphoric diester hydrolase activity GO:0008081 8.62 PDE5A PDE4A

Sources for Vasculogenic Impotence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....